Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Others treat unbranded injectables with heightened suspicion
If confirmed, that mechanism would represent a genuinely novel approach to treating substance use disorders
Ozempic shares the same active ingredient as Wegovy (semaglutide)
Developed to treat symptoms of type 2 diabetes, Ozempic (semaglutide) was licensed for medical use in 2017 by Novo Nordisk
Phase 2 cagrilintide alone ~10.8% body weight reduction at 26 weeks (4.5mg) Phase 2 CagriSema combo ~15.6% body weight reduction at 32 weeks Phase 3 REDEFINE 1 ~22.7% body weight reduction at 68 weeks Phase 2 CagriSema combination trial The Phase 2 trial of CagriSema was published in The Lancet in 2023, and its results attracted immediate attention
The good news: GLP-1 medications do not directly cause melasma or skin pigment disorders
